Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 51: 618-628, 2005. First published January 13, 2005; 10.1373/clinchem.2004.043901
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
clinchem.2004.043901v1
51/3/618    most recent
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (7)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ivaska, K. K.
Right arrow Articles by Väänänen, H. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ivaska, K. K.
Right arrow Articles by Väänänen, H. K.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2005;51:618-628.)
© 2005 American Association for Clinical Chemistry, Inc.


Endocrinology and Metabolism

Urinary Osteocalcin as a Marker of Bone Metabolism

Kaisa K. Ivaska1,a, Sanna-Maria Käkönen1, Paul Gerdhem2, Karl J. Obrant2, Kim Pettersson3 and H. Kalervo Väänänen1

1 Institute of Biomedicine, Department of Anatomy, and 3 Department of Biotechnology, University of Turku, Turku, Finland.
2 Department of Orthopaedics, Malmö University Hospital, Malmö, Sweden.

aAddress correspondence to this author at: Institute of Biomedicine, Department of Anatomy, University of Turku, Kiinamyllynkatu 10, FI-20520 Turku, Finland. Fax 358-2-333-7352; e-mail kaisa.ivaska{at}utu.fi.

Background: Osteocalcin (OC) is produced by osteoblasts during bone formation, and circulating OC has been used in clinical investigations as a marker of bone metabolism. OC is excreted into urine by glomerular filtration and can be found in urine as midmolecule fragments.

Methods: We developed and evaluated three immunoassays (U-MidOC, U-LongOC, and U-TotalOC) for the detection of various molecular forms of urine OC (U-OC). We evaluated the association of U-OC with other markers of bone turnover and with bone mass in 1044 elderly women and studied seasonal and circadian variation of U-OC.

Results: U-OC correlated with other bone turnover markers [Spearman correlation (r), 0.30–0.57; P <0.0001], demonstrating the association between U-OC and skeletal metabolism. There was also a significant association between bone metabolism assessed by U-OC quartiles and bone mass assessed by total body bone mineral content (P <0.0001). The seasonal effects appeared to be rather small, but we observed a significant circadian rhythm similar to the one reported for serum OC with high values in the morning and low values in the afternoon.

Conclusions: The three immunoassays had unique specificities toward different naturally occurring U-OC fragments. U-OC concentrations measured with any of these assays correlated with bone turnover rates assessed by conventional serum markers of bone metabolism. The measurement of OC in urine samples could be used as an index of bone turnover in monitoring bone metabolism.




The following articles in journals at HighWire Press have cited this article:


Home page
J. Clin. Endocrinol. Metab.Home page
K. K. Ivaska, J. Lenora, P. Gerdhem, K. Akesson, H. K. Vaananen, and K. J. Obrant
Serial Assessment of Serum Bone Metabolism Markers Identifies Women with the Highest Rate of Bone Loss and Osteoporosis Risk
J. Clin. Endocrinol. Metab., July 1, 2008; 93(7): 2622 - 2632.
[Abstract] [Full Text] [PDF]


Home page
IBMS BoneKEyHome page
M. E. Kraenzlin
Biochemical Markers of Bone Turnover and Osteoporosis Management
IBMS BoneKEy, July 1, 2007; 4(7): 191 - 203.
[Abstract] [Full Text] [PDF]


Home page
Clin. Chem.Home page
K. K. Ivaska, K. Pettersson, A. Nenonen, K. Uusi-Rasi, A. Heinonen, P. Kannus, and H. K. Vaananen
Urinary Osteocalcin Is a Useful Marker for Monitoring the Effect of Alendronate Therapy
Clin. Chem., December 1, 2005; 51(12): 2362 - 2365.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the American Association for Clinical Chemistry.